Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-06-14-Speech-4-332-250"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20120614.22.4-332-250"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Poly Implant Prothèse (PIP), a French company manufacturing medical devices, has sold more 470 000 breast implants used for women in 71 countries. Some of these implants have caused health problems and had to be removed, causing harm to the patients who agreed for them to be implanted. This motion for a resolution, tabled following the questions for oral answer raised by representatives of all of Parliament’s political groups, concerns the defective silicone gel breast implants made by PIP. I welcome the adoption of a directive on medical acts which prevents misleading advertising and makes companies that produce medical devices accountable. When working with human beings, all stages of the production process, from research during laboratory tests to mass production, should be subject to constant monitoring, because human lives are at stake. Permanent traceability is required in order to increase safety and public confidence. I voted for this motion for a resolution because patient health has to be considered paramount, and we cannot allow any kind of fraud, particularly when it involves medical devices."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples